First Patient Dosed in Phase 3 Trial Testing VB-111 in Platinum-resistant Ovarian Cancer
News
VBL Therapeutics has successfully administered the initial dose to the first patient in its Phase 3 trial investigating the effects of VB-111 (ofranergene obadenovec) in platinum-resistant ovarian cancer. The pivotal OVAL ... Read more